Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: Immunohistochemical approach with potential clinical utility

Cancer Control

Volumn 13, Issue 1, 2006, Pages 52-60

  Nasir, Aejaz ^a   Stridsberg, Mats ^b   Strosberg, Jonathan ^a   Su, Phi Huynh ^c   Livingston, Sandra ^c   Malik, Humaira A ^a   Kelley, Scott T ^a   Centeno, Barbara A ^a   Coppola, Domenico ^a   Malafa, Mokenge E ^a   Yeatman, Timothy J ^a   Kvols, Larry K ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; PARAFFIN; POLYCLONAL ANTIBODY; RECEPTOR SUBTYPE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; RETROSPECTIVE STUDY; SMALL INTESTINE CANCER;

EID: 33644647053     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480601300108     Document Type: Article

References (30)

1. Kwekkeboom DJ, Mueller-Brand J, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):62S-66S.
2. Janson ET, Oberg K. Long-term management of the carcinoid syndrome: treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993;32:225-229.
3. Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut. 1996;39:279-283.
4. Wymenga AN, Eriksson B, Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol. 1999;17:1111.
5. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24:28-47.
6. Kvols LK, Reubi JC, Horisberger U, et al. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J Biol Med. 1992;65:505-518; discussion 531-536.
7. Stafford ND, Condon LT, Rogers MJ, et al. The immunohistochemical localisation of somatostatin receptors 1, 2, 3, and 5 in acoustic neuromas. J Clin Pathol. 2004;57:168-171.
8. Srikant CB. Human somatostatin receptor mediated antiproliferative action evokes subtype selective cytotoxic and cytostatic signaling. Yale J Biol Med. 1997;70:541-548.
9. Sharma K, Srikant CB. Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer. 1998;76:259-266.
10. Reubi JC, Krenning E, Lamberts SW, et al. Somatostatin receptors in malignant tissues. J Steroid Biochem Mol Biol. 1990;37:1073-1077.
11. Reubi JC, Kvols L, Krenning E, et al. In vitro and in vivo detection of somatostatin receptors in human malignant tissues. Acta Oncol. 1991;30:463-468.
12. Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors: a correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 2002;440:461-475.
13. Oda Y, Tanaka Y, Naruse T, et al. Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. Surg Today. 2002;32:690-694.
14. Schulz S, Pauli SU, Handel M, et al. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res. 2000;6:1865-1874.
15. Solcia E, Kloppel G, Sobin LH, eds. Histological Typing of Endocrine Tumors. 2nd ed. New York, NY.: Springer; 2000.
16. Ludvigsen E, Olsson R, Stridsberg M, et al. Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats. J Histochem Cytochem. 2004;52:391-400.
17. Fjallskog ML, Ludvigsen E, Stridsberg M, et al. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol. 2003;20:59-67.
18. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:966-973.
19. McCarthy KE, Woltering EA, Anthony LB. In situ radiotherapy with 111In-pentetreotide: state of the art and perspectives. Q J Nucl Med. 2000;44:88-95.
20. Kvols L, Oberg K, de Herder W, et al. Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR. Proc Annu Meet Am Soc Clin Oncol. 2005. Abstract 8024.
21. Schulz S, Schulz S, Schmitt J, et al. Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res. 1998;4:2047-2052.
22. Schulz S, Schmitt J, Weise W. Frequent expression of immunoreactive somatostatin receptors in cervical and endometrial cancer. Gynecol Oncol. 2003;89:385-390.
23. Reubi JC, Waser B, Liu Q, et al. Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab. 2000;85:3882-3891.
24. Schulz S, Schmitt J, Quednow C, et al. Immunohistochemical detection of somatostatin receptors in human ovarian tumors. Gynecol Oncol. 2002;84:235-240.
25. Kulaksiz H, Eissele R, Rossler D, et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 2002;50:52-60.
26. Mundschenk J, Unger N, Schulz S, et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab. 2003;88:5150-5157.
27. Hornick CA, Anthony CT, Hughey S, et al. Progressive nuclear translocation of somatostatin analogs. J Nucl Med. 2000;41:1256-1263.
28. Bertherat J, Tenenbaum F, Perlemoine K, et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab. 2003;88:5353-5360.
29. Reubi JC, Schaer JC, Laissue JA, et al. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism. 1996;45(8 suppl 1):39-41.
30. Kimura N, Pilichowska M, Date F, et al. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin Cancer Res. 1999;5:3483-3487.